Navigation Links
Sinovac Announces Closing of Common Share Offering
Date:2/2/2010

BEIJING, Feb. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, announced today that its previously announced public common share offering was closed on February 2, 2010. Sinovac received net proceeds of approximately $62.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, which included net proceeds from the sale of 1,500,000 common shares pursuant to the full exercise of the underwriters' over-allotment option.

UBS Securities LLC and Piper Jaffray & Co. served as joint bookrunners for the offering.

The offering was made under Sinovac's currently effective shelf registration statements on Form F-3 filed with the Securities and Exchange Commission on November 18, 2009 and January 27, 2010. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, securities, and does not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from UBS Securities LLC, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, U.S.A., telephone: 888-827-7275, or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, Suite 800, Minneapolis MN 55402, U.S.A., telephone: 1-800-754-4781.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and Panflu.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for a number of different infectious diseases including enterovirus 71, pneumococcal disease, Japanese encephalitis, haemophilus influenzae type b (Hib), meningitis, rabies, chickenpox, mumps and rubella. Sinovac is also conducting field trials for independently developed inactivated animal rabies vaccine.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law.

    For further information, please contact:

    Sinovac Biotech Ltd.
     Helen G. Yang
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
    The Ruth Group
     Amy Glynn/Stephanie Carrington
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
    The Ruth Group
     Janine McCargo
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Sinovac Announces Exercise of Over-Allotment Option
2. Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
3. Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea
4. Sinovacs H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
5. Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
6. Sinovac Reports Unaudited Second Quarter 2009 Financial Results
7. Sinovac Schedules 2008 Annual General Meeting
8. Sinovac Reports Unaudited First Quarter 2009 Financial Results
9. Sinovac Announces that Government Investigation Rules Out Healives Role in Childs Death
10. Sinovac Provides Support to Chinas Ministry of Health to Aid Earthquake Victims
11. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Providing broad access to ... opposition, but there is a better way to address this problem. , That was ... Pharmacy, Public Policy and Economics at the University of Southern California, who served as ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... been named Agency of Record (AOR) for Theravent, Inc. , the makers ... Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand distribution in ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... products, announced an exciting new partnership with the highly regarded and well renowned ... Management’s highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize ...
(Date:4/21/2017)... Salt Lake City, UT (PRWEB) , ... April 21, 2017 , ... ... medical staffing solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has ... the way for the next chapter of growth for our agency and our ability ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 6.35% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/18/2017)... Research and Markets has announced the addition of the ... Radiopharmaceuticals Market, Forecast to 2023" report to their offering. ... This report assesses ... growth in the number of unit shipments over the next ... design and manufacture molecular imaging equipment. Market ...
Breaking Medicine Technology: